Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 2.02, 9.01 · 8-K

Lifevantage Corporation

LFVNNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On August 27, 2026, LifeVantage Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and full fiscal year ended June 30, 2026. A copy of the Company’s press release is attached as Exhibit 99.1 to this report and incorporated by reference.…

Filed Aug 27, 2026Accepted Aug 27, 2026, 4:06 PM EDTCIK 849146Accession 0001193125-26-371265
Share

Company context

LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics - the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the MindBody GLP-1 SystemÒ, the newest comprehensive gut activator from LoveBiome P84, the Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic and hydration energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.

Current securities

Recent company filings

  1. ARS filingSep 18, 2026
  2. DEFA14A filingSep 18, 2026
  3. DEF 14A filingSep 18, 2026
  4. 4 filingSep 17, 2026
  5. 10-K filingAug 27, 2026

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition. On August 27, 2026, LifeVantage Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and full fiscal year ended June 30, 2026. A copy of the Company’s press release is attached as Exhibit 99.1 to this report and incorporated by reference. The information furnished in this Item 2.02 and the exhibit hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Filed exhibits (1)
EX-99.1 (by filename) lfvn-ex99_1.htm

EX-99.1 2 lfvn-ex99_1.htm EX-99.1 EX-99.1 LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2026 Salt Lake City, UT, August 27, 2026, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its fourth fiscal quarter ended June 30, 2026. Fourth Quarter Fiscal 2026 Summary*: • Revenue was $42.4 million, a decrease of 23.1% from the prior year period; • Revenue in the Americas decreased 24.8%, and revenue in Asia/Pacific & Europe decreased 16.9%; • Net income per diluted share was $0.10, versus $0.15 per diluted share a year ago; • Adjusted earnings per diluted share was $0.11, compared to $0.17 a year ago; and • Adjusted EBITDA was $2.7 million compared to $4.8 million a year ago. * All comparisons are on a year over year basis and compare the fourth quarter of fiscal 2026 to the fourth quarter of fiscal 2025, unless otherwise noted. Fiscal Year 2026 Summary*: • Revenue was $182.6 million, a decrease of 20.1% from the prior year period; • Revenue in the Americas decreased 23.2%, and reven…

Open exhibit ↗